Antigenics announced in June results of an interim analysis from the company's ongoing global patient survival registry, which showed that patients with kidney cancer at intermediate risk of disease recurrence demonstrated an approximately 46 percent lower risk of death when treated with Oncophage.

View press release  |  View PDF of poster (464 K)

Antigenics Announces Expansion of Investigator-Sponsored Study for Glioma (6/25/2009)

Antigenics’ QS-21 Adjuvant Enters Pivotal Phase 3 Clinical Trial of GlaxoSmithKline’s Malaria Vaccine (6/17/2009)

Tim Rothwell Joins Antigenics' Board of Directors (6/15/2009)

Antigenics Presents Positive Oncophage® Interim Survival Data at ASCO (6/1/2009)

Antigenics To Webcast 2009 Annual Shareholders Meeting (5/27/2009)

Antigenics Reports First Quarter 2009 Financial Results (5/7/2009)

Antigenics to Report First Quarter 2009 Financial Results on May 7, 2009; Conference Call to Follow (5/4/2009)

All events »